Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Trump Says Anthropic No Longer Seen as National Security Threat 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
HAMPTON, N.J., Feb. 04, 2016 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in a fireside chat at the Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 at 2:40 p.m. EST in New York City.
The live webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentation will be available for seven days following the event.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected]
